547 related articles for article (PubMed ID: 17637772)
21. What should be done to improve the productivity of neurological research?
Moses H; Martin JB
Ann Neurol; 2006 Dec; 60(6):647-51. PubMed ID: 17192925
[No Abstract] [Full Text] [Related]
22. Janelia Farm: an experiment in scientific culture.
Rubin GM
Cell; 2006 Apr; 125(2):209-12. PubMed ID: 16630805
[TBL] [Abstract][Full Text] [Related]
23. Drug discovery. New institute aims to help academics make medicines.
Service RF
Science; 2012 Mar; 335(6074):1288-9. PubMed ID: 22422951
[No Abstract] [Full Text] [Related]
24. Centre stage in Missouri.
Smaglik P
Nature; 2004 Oct; 431(7009):720-1. PubMed ID: 15470434
[No Abstract] [Full Text] [Related]
25. A new era of hope for the world's most neglected diseases.
The
PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
[TBL] [Abstract][Full Text] [Related]
26. Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: yes.
Havrdová E
Mult Scler; 2012 Sep; 18(9):1209-10. PubMed ID: 22936682
[No Abstract] [Full Text] [Related]
27. Research funding. France hatches 67 California wannabes.
Enserink M
Science; 2005 Jul; 309(5734):547. PubMed ID: 16040682
[No Abstract] [Full Text] [Related]
28. Partnership between academia and industry for drug discovery in Alzheimer's disease.
Ivinson AJ; Lane R; May PC; Hosford DA; Carrillo MC; Siemers ER
Alzheimers Dement; 2008 Mar; 4(2):80-8. PubMed ID: 18631952
[TBL] [Abstract][Full Text] [Related]
29. Terms of Scripps-Sandoz agreement may be more common than its critics believe.
Mervis J
Nature; 1993 Mar; 362(6417):194-5. PubMed ID: 8459840
[No Abstract] [Full Text] [Related]
30. Industry-sponsored research.
Okike K; Kocher MS; Mehlman CT; Bhandari M
Injury; 2008 Jun; 39(6):666-80. PubMed ID: 18508054
[TBL] [Abstract][Full Text] [Related]
31. Filling the pipeline for neglected diseases: creation of a medicinal chemistry-centric international drug discovery institute [iDDi].
Kozikowski AP; Reitz AB
Drug Discov Today; 2008 Feb; 13(3-4):97-8. PubMed ID: 18275906
[No Abstract] [Full Text] [Related]
32. Outlook: finding improved medicines: the role of academic-industrial collaboration.
Chin-Dusting J; Mizrahi J; Jennings G; Fitzgerald D
Nat Rev Drug Discov; 2005 Nov; 4(11):891-7. PubMed ID: 16247439
[TBL] [Abstract][Full Text] [Related]
33. The power of two.
Kiser K
Minn Med; 2007 May; 90(5):14-5. PubMed ID: 17550079
[No Abstract] [Full Text] [Related]
34. The Drug Discovery Portal: a resource to enhance drug discovery from academia.
Clark RL; Johnston BF; Mackay SP; Breslin CJ; Robertson MN; Harvey AL
Drug Discov Today; 2010 Aug; 15(15-16):679-83. PubMed ID: 20547242
[TBL] [Abstract][Full Text] [Related]
35. Preclinical drug discovery research and training at Vanderbilt.
Lindsley CW; Weaver D; Jones C; Marnett L; Conn PJ
ACS Chem Biol; 2007 Jan; 2(1):17-20. PubMed ID: 17243778
[No Abstract] [Full Text] [Related]
36. [Industry and pharmaceutical research in Italy. How to make up for lost time].
Mortari U
Recenti Prog Med; 2006 Nov; 97(11):634-9. PubMed ID: 17252720
[TBL] [Abstract][Full Text] [Related]
37. Erosion of the principal investigator role in a climate of industry dominance.
Rowinsky EK
Eur J Cancer; 2005 Oct; 41(15):2206-9. PubMed ID: 16162405
[TBL] [Abstract][Full Text] [Related]
38. Drug discovery.
Kennedy D
Science; 2004 Mar; 303(5665):1729. PubMed ID: 15031461
[No Abstract] [Full Text] [Related]
39. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
40. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
Rai AK; Reichman JH; Uhlir PF; Crossman C
Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
